RxDoctor Payments Data

Jennifer Irwin, PA

Medical · Indianapolis, INNPI 1043309461

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.2% of the total across 1,420 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,267in general payments, 2019–2025

Across 1,420 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$6K
  • AbbVie$4K
  • Livanova USA, Inc.$4K
  • UCB, Inc.$2K
  • Pfizer$1K
  • Jazz Pharmaceuticals Inc.$1K
  • plus $15K from 54 others

What the payments were for

  • Travel & lodging$2,3217%
  • Food & beverage$31,94693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.90$5,843
AbbVie(2 entities)222$3,944
Livanova USA, Inc.24$3,754
UCB, Inc.161$2,471
Pfizer91$1,303
Jazz Pharmaceuticals Inc.46$1,284
SK Life Science, Inc.55$1,133
Novartis49$1,132
Biohaven Pharmaceuticals, Inc.49$889
Eisai Inc.43$839
Biogen35$779
Lilly USA, LLC53$742
Lundbeck LLC22$731
Neurocrine Biosciences, Inc.37$671
Amgen(2 entities)22$643
Neurelis, Inc.25$642
Catalyst Pharmaceuticals, Inc.29$612
AstraZeneca(2 entities)27$532
Biohaven Pharmaceutical Holding Company Ltd.53$493
Teva Pharmaceuticals USA, Inc.35$472
Argenx US, Inc.26$411
MDD US Operations, LLC17$408
Acadia Pharmaceuticals Inc15$351
TG Therapeutics, Inc.16$347
Sanofi6$320
Amneal Pharmaceuticals LLC16$310
Axsome Therapeutics, Inc.17$217
Takeda Pharmaceuticals U.S.A., Inc.8$213
Supernus Pharmaceuticals, Inc.12$191
Zogenix Inc.3$186
Otsuka America Pharmaceutical, Inc.13$184
Greenwich Biosciences, Inc.5$167
CSL Behring7$167
Johnson & Johnson7$155
Alnylam Pharmaceuticals Inc.7$153
Harmony Biosciences LLC4$117
Banner Life Sciences, LLC6$115
Neuropace, Inc.1$93
Bristol Myers Squibb4$87
Genentech USA, Inc.4$79
Tanabe Pharma America, Inc.3$71
Mallinckrodt Hospital Products Inc.3$65
Acorda Therapeutics, Inc4$64
Medtronic4$63
Grifols USA, LLC3$63
Aquestive Therapeutics, Inc.4$63
Cycle Pharmaceuticals Inc3$59
Ipsen Biopharmaceuticals, Inc4$59
PTC Therapeutics, Inc.2$53
Avanir Pharmaceuticals, Inc.3$50
GRT US Holding, Inc.2$42
Impel Pharmaceuticals Inc.2$38
Avadel CNS Pharmaceuticals, LLC2$36
Tersera Therapeutics LLC2$34
Merz Pharmaceuticals, LLC2$32
Vanda Pharmaceuticals Inc.1$29
Abbott1$24
Sumitomo Pharma America, Inc.1$24
Upsher-smith Laboratories LLC1$24
Resmed Corp1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,267 in reported general payments places this provider in the 95th percentile of 273 medical providers in Indiana.

See all medical providers in Indiana

Medicare billing

Part B allowed, 2024
$9,360
Medicare patients
23
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxtellar XrOxcarbazepine34$75,230
EpidiolexCannabidiol (Cbd)19$60,179
LamictalLamotrigine14$34,194
OnfiClobazam12$25,610
Rufinamide20$21,060
FycompaPerampanel12$14,490
Clobazam51$13,265
Lamotrigine OdtLamotrigine23$11,009
Aimovig AutoinjectorErenumab-Aooe13$10,040
Lacosamide56$8,640
Emgality PenGalcanezumab-Gnlm11$7,251
Oxcarbazepine12$3,926
Levetiracetam66$1,939
Scopolamine13$1,218
Divalproex Sodium ErDivalproex Sodium19$934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Supernus Pharmaceuticals, Inc.Oxtellar Xr$191$75,23034 claims
Lundbeck LLCOnfi$731$25,61012 claims
Eisai Inc.Fycompa$839$14,49012 claims
Upsher-smith Laboratories LLCTopiramate$24$57742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 273 medical providers in Indiana.

Other medical in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →